Back to Directory

Charlotte Perlowski

Email

cperlowski@fhi360.org

Phone

919-321-3581

Institution

FHI 360

Title

Clinical Research Manager

Address

FHI 360
359 Blackwell St.
Suite 200
Durham, NC 27701
United States of America

Request an Update

Affiliated Studies

IMPAACT 2038: Phase I Study of the Infectivity, Safety, and Immunogenicity of a Single Dose of Recombinant, Live-Attenuated, Bovine/Human, Parainfluenza Virus Type 3 (B/HPIV3) Vector Vaccines B/HPIV3/RSV/PreF, B/HPIV3/RSV/PreF/TM, or Placebo, Delivered via Nasal Sprayer to HPIV3-Seronegative Children 6 to 24 Months of Age

DAIDS Number

TBD

Research Area

Complications & Comorbidities

Study Status

In Development

IMPAACT 2013: Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, D46/NS2/N/delta M2-2-HindIII, Lot RSV#011B, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age

DAIDS Number

30074

Research Area

Complications & Comorbidities

Study Status

Concluded

P1114: Safety and Immunogenicity of an RSV Vaccine cps2

DAIDS Number

11948

Research Area

Complications & Comorbidities

Study Status

Concluded

P1115: Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission: A Phase I/II Proof of Concept Study

DAIDS Number

11954

Research Area

Cure

Study Status

Enrolling

P1100: AERAS 402

DAIDS Number

11801

Research Area

Tuberculosis

Study Status

Concluded

Show All